Suzhou Aozong Biotechnology

Suzhou Aozong Biotechnology is a clinical-stage biopharmaceutical company based in the Suzhou Industrial Park, China, specializing in the development of innovative therapies for central nervous system (CNS) disorders. The company focuses on the therapeutic application of medical ozone and its derivatives, aiming to address significant unmet needs in the treatment of acute ischemic stroke and neurodegenerative diseases. Its lead candidate, OZ-001, is a first-in-class neuroprotective agent currently in Phase 2 clinical trials, designed to reduce neuronal damage and improve functional recovery in stroke patients. Aozong's research leverages the modulation of oxidative stress pathways, specifically targeting the Nrf2 signaling pathway to enhance cellular defense mechanisms. The company is supported by leading venture capital firms in the region and continues to expand its pipeline of neuroprotective and anti-inflammatory candidates.